United Therapeutics Insider Files Form 144 for 4,560-Share Sale

Rhea-AI Filing Summary

United Therapeutics (UTHR) filed a Form 144 reporting a proposed sale of 4,560 common shares via Morgan Stanley Smith Barney on NASDAQ. The filing states the shares were acquired and are to be sold on 09/10/2025 through a stock option exercise and were paid for in cash on that date. The aggregate market value of the shares to be sold is listed as $1,839,321.60 against 45,226,262 shares outstanding, indicating the sale represents a small fraction of total shares. The filer certifies they know of no undisclosed material adverse information.

Insights

Financial Analyst

TL;DR: Insider exercised options and plans a small-volume sale of 4,560 shares worth $1.84M; not likely material to valuation.

The transaction is an option exercise followed by an intended sale through a broker on NASDAQ. At 4,560 shares versus 45,226,262 outstanding, the position is de minimis relative to total float. The filing discloses cash payment for the exercise and a broker intermediary. From a market-impact perspective, this is routine insider liquidity rather than a strategic corporate action; it provides transparency about insider activity but lacks financial detail to imply broader company performance changes.

Corporate Governance Expert

TL;DR: Form 144 fulfills disclosure obligations for insider sale; no indication of undisclosed material information per signature.

The filer certifies absence of undisclosed material adverse information and notes potential reliance on a trading plan framework. The filing documents acquisition via stock option exercise and cash payment, which are standard mechanics for insiders monetizing equity. Governance-wise, the disclosure meets Rule 144 notice requirements and supports market transparency; there is no disclosure here of any new governance events or departures.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	4560	1839321.60	45226262	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/10/2025	Stock Option Exercise	Issuer			4560	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does United Therapeutics (UTHR) plan to sell according to the Form 144?

The filing reports a proposed sale of 4,560 common shares.

When were the UTHR shares acquired and when is the approximate sale date?

The shares were acquired by stock option exercise on 09/10/2025, and the approximate sale date is 09/10/2025.

What is the aggregate market value and how many UTHR shares are outstanding per the filing?

Aggregate market value is listed as $1,839,321.60 and shares outstanding are 45,226,262.

Which broker and exchange are used for the proposed sale in the UTHR Form 144?

The broker is Morgan Stanley Smith Barney LLC and the sale is on NASDAQ.

How was the purchase price paid for the acquired UTHR shares?

The filing states payment was made in cash on the acquisition date.